Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy
Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional anal...
Gespeichert in:
Veröffentlicht in: | Clinical rheumatology 2011-01, Vol.30 (1), p.7-13 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 13 |
---|---|
container_issue | 1 |
container_start_page | 7 |
container_title | Clinical rheumatology |
container_volume | 30 |
creator | Nguyen, Sheila Hojjati, Mehrnaz |
description | Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy. |
doi_str_mv | 10.1007/s10067-010-1563-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_822362647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>822362647</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</originalsourceid><addsrcrecordid>eNp9kEtv1TAQhS0EoreFH8AGIjZdBWb8iO0lqnhJlRCPri3HmTSp7o2DnYDuv8dXKSCxYOORPd85njmMPUN4hQD6dS5no2tAqFE1otYP2A6lkLW10j5kO9AaaoHWnLHznO8AgBuLj9kZBysaiXbHPn-hHyP9rGJfhTUlmpZqGSj5eaRc9TFVmUKcOp-O1XCcKS0pzsMYqnndH-J0eo55oejTMpSOX4bjE_ao9_tMT-_rBbt59_bb1Yf6-tP7j1dvrusgG1jKWLxrZVBgrerRBE4eDW-NarlolW8Jdas7hC6gDNAYRb4j6EBBLzodhLhgl5vvnOL3lfLiDmMOtN_7ieKaneFcNLyRupAv_yHv4pqmMpwzJTZpFFcFwg0KKeacqHdzGg9lQYfgTmm7LW0Hp3uRuZPx83vjtT1Q90fxO94C8A3IpTXdUvr78_9cX2yi3kfnb9OY3c1XDigALRdKGPEL7u6Ugg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856348525</pqid></control><display><type>article</type><title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Nguyen, Sheila ; Hojjati, Mehrnaz</creator><creatorcontrib>Nguyen, Sheila ; Hojjati, Mehrnaz</creatorcontrib><description>Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-010-1563-7</identifier><identifier>PMID: 20936419</identifier><language>eng</language><publisher>London: London : Springer-Verlag</publisher><subject>Aged ; Antineoplastic Agents - pharmacology ; Bisphosphonates ; Diphosphonates - chemistry ; Female ; Gefetinib ; Humans ; Lung Neoplasms - complications ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; octreotide ; Octreotide - pharmacology ; Osteoarthropathy ; Osteoarthropathy, Secondary Hypertrophic - complications ; Osteoarthropathy, Secondary Hypertrophic - therapy ; Pain ; Quinazolines - pharmacology ; Review Article ; Rheumatology ; Rheumatology - methods ; Secondary hypertrophic ; therapeutics ; Treatment ; Treatment Outcome ; Vagotomy ; Vagotomy - methods</subject><ispartof>Clinical rheumatology, 2011-01, Vol.30 (1), p.7-13</ispartof><rights>Clinical Rheumatology 2010</rights><rights>Clinical Rheumatology 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</citedby><cites>FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-010-1563-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-010-1563-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20936419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Sheila</creatorcontrib><creatorcontrib>Hojjati, Mehrnaz</creatorcontrib><title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.</description><subject>Aged</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Bisphosphonates</subject><subject>Diphosphonates - chemistry</subject><subject>Female</subject><subject>Gefetinib</subject><subject>Humans</subject><subject>Lung Neoplasms - complications</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>octreotide</subject><subject>Octreotide - pharmacology</subject><subject>Osteoarthropathy</subject><subject>Osteoarthropathy, Secondary Hypertrophic - complications</subject><subject>Osteoarthropathy, Secondary Hypertrophic - therapy</subject><subject>Pain</subject><subject>Quinazolines - pharmacology</subject><subject>Review Article</subject><subject>Rheumatology</subject><subject>Rheumatology - methods</subject><subject>Secondary hypertrophic</subject><subject>therapeutics</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><subject>Vagotomy</subject><subject>Vagotomy - methods</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kEtv1TAQhS0EoreFH8AGIjZdBWb8iO0lqnhJlRCPri3HmTSp7o2DnYDuv8dXKSCxYOORPd85njmMPUN4hQD6dS5no2tAqFE1otYP2A6lkLW10j5kO9AaaoHWnLHznO8AgBuLj9kZBysaiXbHPn-hHyP9rGJfhTUlmpZqGSj5eaRc9TFVmUKcOp-O1XCcKS0pzsMYqnndH-J0eo55oejTMpSOX4bjE_ao9_tMT-_rBbt59_bb1Yf6-tP7j1dvrusgG1jKWLxrZVBgrerRBE4eDW-NarlolW8Jdas7hC6gDNAYRb4j6EBBLzodhLhgl5vvnOL3lfLiDmMOtN_7ieKaneFcNLyRupAv_yHv4pqmMpwzJTZpFFcFwg0KKeacqHdzGg9lQYfgTmm7LW0Hp3uRuZPx83vjtT1Q90fxO94C8A3IpTXdUvr78_9cX2yi3kfnb9OY3c1XDigALRdKGPEL7u6Ugg</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Nguyen, Sheila</creator><creator>Hojjati, Mehrnaz</creator><general>London : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</title><author>Nguyen, Sheila ; Hojjati, Mehrnaz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Bisphosphonates</topic><topic>Diphosphonates - chemistry</topic><topic>Female</topic><topic>Gefetinib</topic><topic>Humans</topic><topic>Lung Neoplasms - complications</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>octreotide</topic><topic>Octreotide - pharmacology</topic><topic>Osteoarthropathy</topic><topic>Osteoarthropathy, Secondary Hypertrophic - complications</topic><topic>Osteoarthropathy, Secondary Hypertrophic - therapy</topic><topic>Pain</topic><topic>Quinazolines - pharmacology</topic><topic>Review Article</topic><topic>Rheumatology</topic><topic>Rheumatology - methods</topic><topic>Secondary hypertrophic</topic><topic>therapeutics</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><topic>Vagotomy</topic><topic>Vagotomy - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Sheila</creatorcontrib><creatorcontrib>Hojjati, Mehrnaz</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Sheila</au><au>Hojjati, Mehrnaz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>30</volume><issue>1</issue><spage>7</spage><epage>13</epage><pages>7-13</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.</abstract><cop>London</cop><pub>London : Springer-Verlag</pub><pmid>20936419</pmid><doi>10.1007/s10067-010-1563-7</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0770-3198 |
ispartof | Clinical rheumatology, 2011-01, Vol.30 (1), p.7-13 |
issn | 0770-3198 1434-9949 |
language | eng |
recordid | cdi_proquest_miscellaneous_822362647 |
source | MEDLINE; SpringerLink Journals |
subjects | Aged Antineoplastic Agents - pharmacology Bisphosphonates Diphosphonates - chemistry Female Gefetinib Humans Lung Neoplasms - complications Male Medicine Medicine & Public Health Middle Aged octreotide Octreotide - pharmacology Osteoarthropathy Osteoarthropathy, Secondary Hypertrophic - complications Osteoarthropathy, Secondary Hypertrophic - therapy Pain Quinazolines - pharmacology Review Article Rheumatology Rheumatology - methods Secondary hypertrophic therapeutics Treatment Treatment Outcome Vagotomy Vagotomy - methods |
title | Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T07%3A44%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20current%20therapies%20for%20secondary%20hypertrophic%20pulmonary%20osteoarthropathy&rft.jtitle=Clinical%20rheumatology&rft.au=Nguyen,%20Sheila&rft.date=2011-01-01&rft.volume=30&rft.issue=1&rft.spage=7&rft.epage=13&rft.pages=7-13&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-010-1563-7&rft_dat=%3Cproquest_cross%3E822362647%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=856348525&rft_id=info:pmid/20936419&rfr_iscdi=true |